Zacks Investment Research downgraded shares of Johnson & Johnson (NYSE:JNJ) from a buy rating to a hold rating in a research report report published on Tuesday.

According to Zacks, “J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, currency impact and lower HCV revenues. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. We believe J&J’s diversified business model, deep pipeline, lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations. We expect the company to continue pursuing bolt-on acquisitions and deals to boost its portfolio. J&J has a deep and promising pipeline with a good new product launch record. However, challenges for the company remain in the form of generic competition, pricing pressure and pipeline setbacks. “

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Several other brokerages have also weighed in on JNJ. RBC Capital Markets reissued an outperform rating and set a $133.00 price objective (up previously from $125.00) on shares of Johnson & Johnson in a report on Wednesday, July 20th. Leerink Swann reaffirmed an outperform rating and issued a $140.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Royal Bank Of Canada boosted their price target on Johnson & Johnson from $125.00 to $133.00 and gave the company an outperform rating in a research note on Wednesday, July 20th. BMO Capital Markets reaffirmed an outperform rating and issued a $132.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Finally, Deutsche Bank AG reaffirmed a hold rating and issued a $142.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a research note on Thursday, July 21st. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $119.53.

Johnson & Johnson (NYSE:JNJ) opened at 119.46 on Tuesday. The firm has a market capitalization of $326.83 billion, a price-to-earnings ratio of 22.26 and a beta of 0.61. The company’s 50-day moving average price is $120.13 and its 200-day moving average price is $116.17. Johnson & Johnson has a 12-month low of $89.90 and a 12-month high of $126.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The company had revenue of $18.50 billion for the quarter, compared to analyst estimates of $17.98 billion. Equities analysts expect that Johnson & Johnson will post $6.69 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were issued a $0.80 dividend. The ex-dividend date of this dividend was Friday, August 19th. This represents a $3.20 annualized dividend and a dividend yield of 2.68%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.15%.

In other news, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the transaction, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the transaction, the vice president now directly owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Horizon Investments LLC boosted its position in Johnson & Johnson by 0.3% in the second quarter. Horizon Investments LLC now owns 2,349 shares of the company’s stock valued at $285,000 after buying an additional 8 shares in the last quarter. Landmark Financial Advisors LLC boosted its position in Johnson & Johnson by 0.5% in the second quarter. Landmark Financial Advisors LLC now owns 1,979 shares of the company’s stock valued at $240,000 after buying an additional 9 shares in the last quarter. Lbmc Investment Advisors LLC boosted its position in Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $457,000 after buying an additional 16 shares in the last quarter. Stratford Consulting LLC boosted its position in Johnson & Johnson by 0.6% in the second quarter. Stratford Consulting LLC now owns 3,201 shares of the company’s stock valued at $388,000 after buying an additional 18 shares in the last quarter. Finally, Taylor Wealth Management Partners boosted its position in Johnson & Johnson by 1.3% in the second quarter. Taylor Wealth Management Partners now owns 1,505 shares of the company’s stock valued at $183,000 after buying an additional 20 shares in the last quarter. 65.32% of the stock is owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.